Looking beyond Avastin
Doctors look ahead to new treatment options for metastatic breast cancer
As clinicians reduce their use of Avastin bevacizumab for metastatic breast cancer, they are looking hopefully toward the more than 24 targeted therapies in Phase II or Phase III trials for metastatic HER2-negative breast cancer.
Some clinicians also suggest Avastin, a mAb against VEGF, could find another spot in this expanding breast cancer armamentarium.
"There are many active drugs available, and I think patients can still feel comfortable with their choices," said Generosa Grana, head of the division of hematology/oncology and director of the Cooper Cancer Institute.